Diabetic Nephropathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Diabetic Nephropathy – Drugs In Development, 2024 report and make more profitable business decisions.
Diabetic nephropathy is damage to the kidney occurring due to diabetes. It is characterized by albuminuria, a reduction in glomerular filtration rate (GFR), and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels, and smoking. This condition is managed by medication and dietary modification.
The Diabetic Nephropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Diabetic Nephropathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 65 molecules, with 58 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Diabetic Nephropathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Diabetic Nephropathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Diabetic Nephropathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Algomedix IncAmakos Biotherapeutics Inc
AptaBio Therapeutics Inc
Artelo Biosciences Inc
Astellas Pharma Inc
AstraZeneca Plc
Boehringer Ingelheim International GmbH
CCRP Therapeutics GmbH
Celros Biotech Co Ltd
Central South University
Chinook Therapeutics Inc
Curacle Co Ltd
Daiichi Sankyo Co Ltd
DiaMedica Therapeutics Inc
Dimerix Ltd
Enyo Pharma SA
Frontbio Co Ltd
Future Medicine Co Ltd
Glycadia Inc
Gmax Biopharm LLC
GNI Group Ltd
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Nanxin Pharmaceutical Co Ltd
Inovio Pharmaceuticals Inc
Inversago Pharma Inc
Lactocore Inc
Landos Biopharma Inc
MD Healthcare Inc
MediPost Co Ltd
Mesoblast Ltd
Mitsubishi Tanabe Pharma Corp
NEPHRIS Srl
Ningxia Kangya Pharmaceutical Co Ltd
Notitia Biotechnologies Co
Orbsen Therapeutics Ltd
Palatin Technologies Inc
PhytoHealth Corp
Poxel SA
Prokidney Corp
RAGE Biotech Pty Ltd
Rebus Holdings Inc
Regenerate Therapeutics Inc
Scohia Pharma Inc
Secarna Pharmaceuticals GmbH & Co KG
Serodus ASA
Shanghai Alebund Pharmaceuticals Ltd
Shanghai Henlius Biotech Inc
Shanghai Pharmaceutical Group Co Ltd
Shanxi University of TCM
Shenzhen Crystal Egg Biomedical Technology Co Ltd
Stony Brook University
UAB Minority Health and Health Equity Research Center
University of Louisville
University of Queensland
Wenzhou Medical University
Wuxi Biocity Biopharma Co Ltd
XORTX Therapeutics Inc
YIRUI Pharmaceutical Technology Co Ltd
ZyVersa Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Diabetic Nephropathy reports